. Author manuscript; available in PMC: 2019 Jul 1.

Published in final edited form as: Aliment Pharmacol Ther. 2018 May 30;48(2):127–137. doi: 10.1111/apt.14823

Table 2.

Characteristics of studies with direct comparisons of HCC recurrence rates

Author Year	Study location	Study Arms	Number of patients	Comparison of Recurrence
Virlogeux 2017²²	France	DAA-treated and untreated	23/45	1.7 vs. 4.2/100 person-months in DAA-treated and untreated patients (adjusted HR 0.24, 95%CI 0.10 – 0.55)
ANRS 2016²⁴	France	DAA-treated and untreated	189/78	0.73 vs. 0.66/100 person-months in DAA-treated and untreated patients (adjusted HR 1.04, 95%CI 0.53 – 2.07)
ANRS 2016²⁴	France	DAA-treated and untreated	13/66	1.1 vs. 1.7/100 person-months in DAA-treated and untreated patients (adjusted HR 0.40, 95%CI 0.05 – 3.03)
Granata 2017³⁰	Italy	DAA-treated and untreated	65/186	Time to recurrence: 23.2 vs. 23.0 months in DAA-treated and untreated patients
Yasui 2017³²	Japan	DAA-treated and IFN-treated	46/26	Proportion: 14% vs. 22% in DAA-treated and IFN-treated (p=0.50)
Joko 2017⁴¹	Japan	DAA-treated and IFN-treated	368/148	No difference in early recurrence between DAA-treated and IFN-treated patients
Ohki 2017³⁴	Japan	DAA-treated, IFN-treated, and untreated	20/20/20	35% vs. 55% vs. 55% in DAA-treated, IFN-treated, and untreated patients (p=0.38)
Singal 2017³⁷	USA	DAA-treated and untreated	207/127	Proportion: 46% vs. 50% in DAA-treated and untreated patients (adjusted OR 0.80, 95%CI 0.48-1.35)
Tanaka 2017⁴²	Japan	DAA-treated, IFN-treated, and untreated	16/16/119	Lower recurrence in DAA-treated than untreated group (adjusted HR 0.56, 95%CI 0.26-0.97)

DAA – direct acting antiviral; IFN - interferon